Incyte Corp. Stock Slides 8.6%, Underperforms Competitors

Dow Jones

Mar 18, 2025

This article was automatically generated by Dow Jones using technology from Automated Insights.

Shares of Incyte Corp. shed 8.6% to $62.01 on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.6% to 5,675.12 and the Dow Jones Industrial Average rising 0.9% to 41,841.63.

Incyte Corp. closed 26.1% below its 52-week high of $83.95, which the company reached on November 8th.

The stock underperformed when compared to some of its competitors, as Alnylam Pharmaceuticals Inc. rose 4.7% to $253.11, Bio-Techne Corp. rose 0.7% to $62.58, and BioMarin Pharmaceutical Inc. rose 3.04% to $71.55.

Trading volume totaled 5.2 million, compared to the 50-day average of 1.6 million.

Data source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

March 17, 2025 16:33 ET (20:33 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2520859336"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2520859336\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2520859336?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-18 04:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520859336","market":"sg","top_or_hot":-1,"title":"Incyte Corp. Stock Slides 8.6%, Underperforms Competitors","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  This article was automatically generated by Dow Jones using technology from Automated Insights. \n</p>\n<p>\n     Shares of Incyte Corp. shed 8.6% to $62.01 on what proved to be an all-around positive trading session for the stock market, with the S&amp;P 500 Index rising 0.6% to 5,675.12 and the Dow Jones Industrial Average rising 0.9% to 41,841.63. \n</p>\n<p>\n     Incyte Corp. closed 26.1% below its 52-week high of $83.95, which the company reached on November 8th. \n</p>\n<p>\n     The stock underperformed when compared to some of its competitors, as Alnylam Pharmaceuticals Inc. rose 4.7% to $253.11, Bio-Techne Corp. rose 0.7% to $62.58, and BioMarin Pharmaceutical Inc. rose 3.04% to $71.55. \n</p>\n<p>\n     Trading volume totaled 5.2 million, compared to the 50-day average of 1.6 million. \n</p>\n<p>\n  Data source: Dow Jones Market Data, FactSet \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 17, 2025 16:33 ET (20:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte Corp. Stock Slides 8.6%, Underperforms Competitors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte Corp. Stock Slides 8.6%, Underperforms Competitors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-18 04:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  This article was automatically generated by Dow Jones using technology from Automated Insights. \n</p>\n<p>\n     Shares of Incyte Corp. shed 8.6% to $62.01 on what proved to be an all-around positive trading session for the stock market, with the S&amp;P 500 Index rising 0.6% to 5,675.12 and the Dow Jones Industrial Average rising 0.9% to 41,841.63. \n</p>\n<p>\n     Incyte Corp. closed 26.1% below its 52-week high of $83.95, which the company reached on November 8th. \n</p>\n<p>\n     The stock underperformed when compared to some of its competitors, as Alnylam Pharmaceuticals Inc. rose 4.7% to $253.11, Bio-Techne Corp. rose 0.7% to $62.58, and BioMarin Pharmaceutical Inc. rose 3.04% to $71.55. \n</p>\n<p>\n     Trading volume totaled 5.2 million, compared to the 50-day average of 1.6 million. \n</p>\n<p>\n  Data source: Dow Jones Market Data, FactSet \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 17, 2025 16:33 ET (20:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INCY","symbol_name":"因塞特医疗","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2520859336","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520859336","pubTimestamp":1742243580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Incyte Corp. shed 8.6% to $62.01 on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.6% to 5,675.12 and the Dow Jones Industrial Average rising 0.9% to 41,841.63.Incyte Corp. closed 26.1% below its 52-week high of $83.95, which the company reached on November 8th.The stock underperformed when compared to some of its competitors, as Alnylam Pharmaceuticals Inc. rose 4.7% to $253.11, Bio-Techne Corp. rose 0.7% to $62.58, and BioMarin Pharmaceutical Inc. rose 3.04% to $71.55.Trading volume totaled 5.2 million, compared to the 50-day average of 1.6 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"INCY":"因塞特医疗"},"translate_title":"Incyte Corp.股价下跌8.6%，表现逊于竞争对手","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":1},"content_text":"This article was automatically generated by Dow Jones using technology from Automated Insights. \n\n\n     Shares of Incyte Corp. shed 8.6% to $62.01 on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.6% to 5,675.12 and the Dow Jones Industrial Average rising 0.9% to 41,841.63. \n\n\n     Incyte Corp. closed 26.1% below its 52-week high of $83.95, which the company reached on November 8th. \n\n\n     The stock underperformed when compared to some of its competitors, as Alnylam Pharmaceuticals Inc. rose 4.7% to $253.11, Bio-Techne Corp. rose 0.7% to $62.58, and BioMarin Pharmaceutical Inc. rose 3.04% to $71.55. \n\n\n     Trading volume totaled 5.2 million, compared to the 50-day average of 1.6 million. \n\n\n  Data source: Dow Jones Market Data, FactSet \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 17, 2025 16:33 ET (20:33 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}